Article Per Year (5 Year)
p-Index From 2020 - 2025
1.037
P-Index
This Author published in this journals
All Journal journal of internal medicine Indonesian Journal of Cancer The Indonesian Biomedical Journal Molecular and Cellular Biomedical Sciences (MCBS) Biomolecular and Health Science Journal JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Ami Ashariati
Medical Hematology Oncology Division, Department Of Internal Medicine, Faculty Of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital Surabaya, Indonesia
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Case Report of Malignant Lymphoma of the Breast ASHARIATI, AMI; DJATMIKO, ARIO; ALI, ISKANDAR
Indonesian Journal of Cancer Vol 8, No 1 (2014): Jan - Mar 2014
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Four cases of breast malignant lymphoma (BML) are discussed, diagnosed and managed. The issue of diagnosing BML, showed how different these 4 cases were, in particular in the imaging ultrasonography (USG). Generally, the USG of ductal carcinoma is irregular solid mass, while the USG of BML is compliant with cystic forms. Case 1 is 68 years old woman with left breast tumor. USG revealed hypoechoic lesion in the left breast with FNA result of malignant lymphoma, but still differential diagnosis with ductal carcinoma of the breast Mamma. Case 2 is a 52 years old woman who had left breast tumor. The USG revealed malignant lesion, left axilla node positive, although FNA result was ductal carcinoma, after simple mastectomy, the frozen section revealed malignant lymphoma. Case 3 is a 51 years old woman, USG of the left breast revealed malignant lesion, left axilla node positive, and excision biopsy revealed non-Hodgkin’s lymphoma diffuse large cell. Case 4 is a 51 years old woman, the USG revealed irregular hypoechoic lesions in both breasts and left supraclavicula node 5 mm. Core biopsy revealed bilateral breast non Hodgkin’s lymphoma subcutaneous, T-cell lymphoma. The therapeutic management of breast lymphoma is controversial and is not fully established yet. A strategy consisting of three cycles of CHOP followed by involved-field radiation therapy is reportedly superior to eight cycles of CHOP alone.
Case Report of Malignant Lymphoma of the Breast ASHARIATI, AMI; DJATMIKO, ARIO; ALI, ISKANDAR
Indonesian Journal of Cancer Vol 8, No 1 (2014): Jan - Mar 2014
Publisher : Indonesian Journal of Cancer

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Four cases of breast malignant lymphoma (BML) are discussed, diagnosed and managed. The issue of diagnosing BML, showed how different these 4 cases were, in particular in the imaging ultrasonography (USG). Generally, the USG of ductal carcinoma is irregular solid mass, while the USG of BML is compliant with cystic forms. Case 1 is 68 years old woman with left breast tumor. USG revealed hypoechoic lesion in the left breast with FNA result of malignant lymphoma, but still differential diagnosis with ductal carcinoma of the breast Mamma. Case 2 is a 52 years old woman who had left breast tumor. The USG revealed malignant lesion, left axilla node positive, although FNA result was ductal carcinoma, after simple mastectomy, the frozen section revealed malignant lymphoma. Case 3 is a 51 years old woman, USG of the left breast revealed malignant lesion, left axilla node positive, and excision biopsy revealed non-Hodgkins lymphoma diffuse large cell. Case 4 is a 51 years old woman, the USG revealed irregular hypoechoic lesions in both breasts and left supraclavicula node 5 mm. Core biopsy revealed bilateral breast non Hodgkins lymphoma subcutaneous, T-cell lymphoma. The therapeutic management of breast lymphoma is controversial and is not fully established yet. A strategy consisting of three cycles of CHOP followed by involved-field radiation therapy is reportedly superior to eight cycles of CHOP alone.
ASOSIASI CA 125 DENGAN RESPON TERAPI PADA PENDERITA LIMFOMA NON-HODGKIN AGRESIF YANG MENDAPAT KEMOTERAPI CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE (CHOP) S, Merlyna; Mulyono, Adi; -, Ugroseno; Putra Sedana, Made; Ashariati, Ami; -, Sugianto; -, Boediwarsono; -, Soebandiri
journal of internal medicine Vol. 12, No. 3 September 2011
Publisher : journal of internal medicine

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (449.126 KB)

Abstract

Cancer antigen (CA) 125 is a glycoprotein produced by epithelial ovarium tumors and mesothelial cells, its levels alsohave been shown to be elevated in patients with Non-Hodgkin!s Lymphoma (NHL). Several papers have reported anassociation of high CA 125 serum levels with advanced NHL as well as relationship between high CA 125 values and pooroutcome. This study aimed to determine association between CA 125 levels (> 35 U/ml) with normal CA 125 (  35 U/ml)to the respone of NHL patients receiving chemotherapy CHOP. An observational analytic prospective study was done in40 patients with NHL at Dr Soetomo Hospital Surabaya. The patient were recruited from both inpatient and outpatientclinic and the initial CA 125 level had determined before the patients received chemotherapy with Cyclophosphamide,Doxorubicin, Vincristine and Prednisone (CHOP). Of the 40 patients who included in this study, 62.5% were male, 37.5%were female, the average age 43,45 years, the most kind of histophatology result were diffuse large cell, cleaved or noncleaved cell (47.5%). There was a signiÞ cant association between CA 125 levels with therapy respone groups (responiveand unresponive), with signiÞ cancy 0.001 (OR 23.22; CI 95%), and with therapy respone groups (CR, PR, NC, PD) withsigniÞ cancy 0.013. The group with normal CA 125 levels (  35 U/ml), had better respone, it was around 95% responive(CR = 35%, PR = 60%) and 5% unresponive (NC = 5%, PD = 0%) than the group who had high CA 125 levels (> 35U/ml), it was only 45% responive (CR = 15%, PR = 30% and 55% unresponive (NC = 50%, PD = 5%). As a conclusion,levels of CA 125 (> 35 U/ml) perhaps could be a negative prognostic factor to predict the CHOP chemotherapy responein NHL patients.
Dedifferentiation of MCF-7 Breast Cancer Continuous Cell Line, Development of Breast Cancer Stem Cells (BCSCs) Enriched Culture and Biomarker Analysis Ami Ashariati Prayogo; Andi Yasmin Wijaya; Winona May Hendrata; Steven Sheng Looi; Reny I’tishom; Lukman Hakim; Fedik Abdul Rantam; I Ketut Sudiana; Abdurachman Abdurachman
The Indonesian Biomedical Journal Vol 12, No 2 (2020)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v12i2.977

Abstract

BACKGROUND: Cancer stem cells (CSCs) eradication might serve as a robust approach for cancer eradication. MCF-7 as breast cancer continuous cell line is known to contain breast CSCs (BCSCs) for its capability to maintain its original tumor population. CSCs enriched culture is a fundamental tool for CSCs targeted therapy development. Effective and unsophisticated CSCs dedifferentiation protocol for producing CSCs enriched culture is needed.METHODS: MCF-7 cells were cultured initially in Dulbecco's Modified Eagle Medium (DMEM) low glucose medium then changed to DMEM:F12. Serum starvation was performed during each medium refreshment gradually with fetal bovine serum (FBS) concentration of 10%, 5%, 2.5% until reaching 1% FBS concentration. Stable MCF-7 culture was then adapted to serum free culture system, containing DMEM:F12, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and B27 supplement as dedifferentiation protocol for 18 days. Cluster of differentiation (CD)44 and CD24 double staining immunocytochemistry was performed to evaluate cell stemness.RESULTS: The population of cells expressing BCSCs markers (CD44+/CD24low) in non-adherent single cells subpopulation was significantly increased after the dedifferentiation procedure (70.39%) compared to control groups (0.71%) (p<0.05). In contrast, the expression of BCSCs marker in adherent single cells subpopulation and for both adherent and non-adherent mammosphere the BCSCs markers showed a stable expression.CONCLUSION: BCSCs enrichment of breast cancer cell cultures from MCF-7 breast cancer cell line can be performed. Breast cancer cell plasticity is observed during the dedifferentiation protocol. Development of dedifferentiation inducing protocols can serve as an important foundation for breast cancer therapy development through BCSCs elimination.KEYWORDS: breast neoplasms, cell line, dedifferentiation, immunohistochemistry, neoplastic stem cells
Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients Merlyna Savitri; Ugroseno Yudho Bintoro; Made Putra Sedana; Muhammad Noor Muhammad; Pradana Zaky Romadhon; Putu Niken Ayu Amrita; Andi Yasmin Wijaya; Winona May Hendrata; Ami Ashariati Prayogo
The Indonesian Biomedical Journal Vol 12, No 2 (2020)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v12i2.1142

Abstract

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21
The Role of JAK2 in Myeloproliferative Diseases Diagnosis Yudith Annisa Ayu Rezkitha; S. Ugroseno Yudho Bintoro; Ami Ashariati
Biomolecular and Health Science Journal Vol. 1 No. 2 (2018): Biomolecular and Health Science Journal
Publisher : Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (572.416 KB) | DOI: 10.20473/bhsj.v1i2.9831

Abstract

Janus Kinase 2 (JAK2) plays an important role in mediating transduction signal of hematopoiesis, including in the pathogenesis of Myeloproliferative diseases (MPD). Various studies have been carried out to identify the position of aleles in tyrosine encoding mutations. Although the effect of JAK2 mutations is still not fully understood, the discovery of these mutations might be able to differentiate the types of polycythaemia vera, essential thrombocytemia, and primary myelofibrosis with malignant abnormalities. WHO has revised the MPD diagnosis criteria following this finding. This review will discuss the role of JAK2.
A 40-year-old Woman with Hypercalcemia Crisis Caused by Bone Metastasis in Stage IV Breast Cancer Wiharjo Hadisuwarno; Merlyna Savitri; Ami Ashariati; S. Ugroseno Yudho Bintoro; M. Noor Diansyah; Putu Niken Ayu Amrita; Pradana Zaky Romadhon
Biomolecular and Health Science Journal Vol. 4 No. 2 (2021): Biomolecular and Health Science Journal
Publisher : Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bhsj.v4i2.29633

Abstract

Breast cancer is still global burden especially for woman with 2.3 million cases every year dan 15% mortality among cancer diseases. In developing countries, most of the cases are diagnosed at terminal stage when metastasis already found. Bone metastasis is the highest among other metastasis sites such as: lung, liver and brain. Bone metastasis will cause hypercalcemia and bone pain as complications.  Both will gradually decrease patient’s quality of life. Comprehensive and holistic management for these complications will reduce deterioration and hopefully increase patient’s quality of life even they were at terminal stage. We describe a 40-year-old woman who got hypercalcemia crisis. Hypercalcemia usually manifest as a consequence of other diseases. Epidemiologically, majority come from metastasis, but can be other diseases, such as multiple myeloma. Interestingly, during medical investigation through her medical history, and physical examination, and laboratory examinations, we conclude that her hypercalcemia crisis was caused by bone metastasis from breast cancer.
Diathesis Hemorrhagic, Coagulation and Fibrinolytic System Rizky Amalia Putri; Muhammad Noor Diansyah; Ami Ashariati Ashariati; Siprianus Ugroseno Yudho Bintoro; Putu Niken Ayu Amrita; Merlyna Savitri Savitri; Pradana Zaky Romadhon
Biomolecular and Health Science Journal Vol. 5 No. 1 (2022): Biomolecular and Health Science Journal
Publisher : Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bhsj.v5i1.35280

Abstract

Bleeding is one of the most common complaints when coming to the hospital which can be mild to life-threatening. The balance of the impaired hemostasis system allows for abnormal bleeding such as hemorrhagic diathesis. Balance between blood clotting and bleeding is always maintained in the body under normal physiology. The coagulation system stops existing bleeding with vasoconstricts of blood vessels and the formation of early platelet plugs, this blockage is strengthened by the presence of a cascade of coagulations to form stable and sturdy blockages. Once bleeding has stopped, the fibrinolytic pathway is initiated to dissolve the blood clot to restore normal blood flow. balance the coagulants, fibrinolytic and inhibitor systems, creating a perfect physiological balance. Hemostatic imbalance is a global problem that can lead to thrombosis or hemorrhage.
Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages Nur Imroatul Mursyidah; Ami Ashariati; Etty Hary Kusumastuti
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 10 No. 1 (2019): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (509.818 KB) | DOI: 10.20473/juxta.V10I12019.38-43

Abstract

Introduction: The aims of this study was to determine the differences of  breast cancer survival rate based on Pathological stages.Methods: This study was conducted with a retrospective case control design using secondary data from Dr. Soetomo General Hospital's medical records. The technique used to take the samples was purposive sampling. The sample was 45 breast cancer patients in Dr. Soetomo General Hospital In January 2015, that able to be contacted again and had a medical record in the oncology center in Dr. Soetomo General Hospital Surabaya. The variables studied is breast cancer survival based on the pathological stages.Results: Breast cancer patients at the stage of IIA have 100% 3-year survival rate, stage IIB by 83.3%, stage IIIA by 71.4%, stage IIIB by 53.8%, IIIC by 50%, and stage IV by 30%. With a comparison of the log-rank significance p = 0.104.Conclusion: The survival rate of breast cancer patients is lower in line with the increasing pathological stage of breast cancer.
Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months Andy Purnomo; Ugroseno Yudho Bintoro; Made Putra Sedana; Ami Ashariati
Molecular and Cellular Biomedical Sciences Vol 3, No 2 (2019)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v3i2.56

Abstract

Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent of Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis.Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed using Fisher exact test which was considered significant if p<0.05.Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin was 9.1 g/dL, median leukocyte was 180x109 /L, median thrombocyte was 645x109 /L, median eosinophil was 2.9%, median basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic response with imatinib.Keywords: Hasford score, hematologic response, CML, imatinib
Co-Authors Abdurachman Abdurachman Adi Mulyono Andi Yasmin Wijaya Andy Purnomo ARIO DJATMIKO, ARIO Bintoro, Siprianus Ugroseno Yudho Boediwarsono - Choirina Windradi Fedik Abdul Rantam I'tishom, Reny ISKANDAR ALI, ISKANDAR Krisnina Nurul Widiyastuti KUSUMASTUTI, ETTY HARY Lukman Hakim Made Putra Sedana Merlyna S Merlyna Savitri Merlyna Savitri Merlyna Savitri Merlyna Savitri Savitri Muhammad Noor Diansyah Muhammad Noor Muhammad Nur Imroatul Mursyidah Putu Niken Ayu Amrita Putu Niken Ayu Amrita Putu Niken Ayu Amrita Putu Niken Ayu Amrita Rizky Amalia Putri Romadhon, Pradana Zaky S.Pd. M Kes I Ketut Sudiana . Soebandiri - Steven Sheng Looi Sugianto - Ugroseno - Ugroseno Yudho Bintoro Ugroseno Yudho Bintoro Wiharjo Hadisuwarno Winona May Hendrata Yudith Annisa Ayu Rezkitha, Yudith Annisa Ayu